Updating the approach to Crohn's disease.
Recognizing clinical and pathologic scenarios, rather than ordering definitive tests, is still the basis for diagnosis of Crohn's disease. Steroids, salicylates, immunomodulating agents, and surgery remain the focus of treatment. The advent of infliximab, however, offers a new therapeutic option for patients with refractory disease.
Hanauer
S B
SB
Section of Gastroenterology, University of Chicago Medical Center, USA.
D000328:Adult; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D007421:Intestine, Small / Q000601:surgery; D011247:Pregnancy
D000911:Antibodies, Monoclonal; D000069285:Infliximab